XiaoMi-AI文件搜索系统
World File Search SystemParainfluenza
将颜色带到分子诊断2023
does not cross-react with the below pathogens: SARS-Cov, MERS-COV, Human Coronaviruses (HCOV-229E, HCOV-OC43, HCOV-NL63, HCOV- HKU1), Adenovirus, Influenza, PARAINFLUENZA 1, ParainFluenza 1, Parainfluenza 2, Parainfluenza 3, Parechovirus, Candida albicans, Legionella non-Pneumophila, Bacillus, Moraxella catarrhalis, Neisseria removed, Neisseria Meningitides, RSV A, RSV B, Rhinovirus, Pseudomonas aeruginosa, Staphylococcus, Streptococcus Leptospirosis, Coxiella burnetii (q- fegetii (q- fegetii（q- fegetii（Q- fegetii（Q-发烧），葡萄球菌表皮，肠病毒，嗜血杆菌，bordetella parapertusis，bordetella parapertusis，bordetella parapertusis，borcoplasmoniae pneumoniae，chamemydia pneumoniae pneumydia pneumydia pneumoniaiaiaiaiae beypeionelly perimopliation sepatis hepatity hepat hepat hepat hepat hepat hepat hepat; Hepatitis Delta, human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, JCV, BKV, Human Papilloma, Parvovirus, herpes simple virus, Mycobacterium tuberculosis, Aspergillus spp., Brucella abortus, Brucella, E.Coli O157, Salmonella spp., Listeria monocytogenes div>does not cross-react with the below pathogens: SARS-Cov, MERS-COV, Human Coronaviruses (HCOV-229E, HCOV-OC43, HCOV-NL63, HCOV- HKU1), Adenovirus, Influenza, PARAINFLUENZA 1, ParainFluenza 1, Parainfluenza 2, Parainfluenza 3, Parechovirus, Candida albicans, Legionella non-Pneumophila, Bacillus, Moraxella catarrhalis, Neisseria removed, Neisseria Meningitides, RSV A, RSV B, Rhinovirus, Pseudomonas aeruginosa, Staphylococcus, Streptococcus Leptospirosis, Coxiella burnetii (q- fegetii (q- fegetii（q- fegetii（Q- fegetii（Q-发烧），葡萄球菌表皮，肠病毒，嗜血杆菌，bordetella parapertusis，bordetella parapertusis，bordetella parapertusis，borcoplasmoniae pneumoniae，chamemydia pneumoniae pneumydia pneumydia pneumoniaiaiaiaiae beypeionelly perimopliation sepatis hepatity hepat hepat hepat hepat hepat hepat hepat; Hepatitis Delta, human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, JCV, BKV, Human Papilloma, Parvovirus, herpes simple virus, Mycobacterium tuberculosis, Aspergillus spp., Brucella abortus, Brucella, E.Coli O157, Salmonella spp., Listeria monocytogenes div>
相信鼻内呼吸道疫苗......
INFORCE 3® 是一种创新疫苗，可保护肉牛和奶牛免受常见肺炎病毒病原体的侵害：牛呼吸道合胞病毒 (BRSV)、传染性牛鼻气管炎 (IBR) 和副流感病毒 3 (PI 3)。
高风险同种异体或自体BMT或白血病患者的病毒呼吸道感染的诊断和管理
Contents Scope ..................................................................................................................................................... 2 1.Introduction ................................................................................................................................ 2 1.1.High-risk criteria ........................................................................................................................ 2 2.Diagnosis .................................................................................................................................... 2 2.1.Samples ................................................................................................................................... 2 2.2.Investigations ............................................................................................................................ 2 3.Minimising infection spread ...................................................................................................... 3 3.1.Inpatients .................................................................................................................................. 3 3.2.Inpatient visitors/relatives .......................................................................................................... 3 3.3.Outpatients ............................................................................................................................... 3 3.4.Staff .......................................................................................................................................... 3 3.5.Staff illness ............................................................................................................................... 4 3.6.Environment or equipment ........................................................................................................ 4 4.Management ............................................................................................................................... 4 4.1.Respiratory Syncytial Virus (RSV)........................................................................................ 4 4.2.Investigations ............................................................................................................................ 4 4.3.Treatment criteria ...................................................................................................................... 4 4.4.Treatment algorithm .................................................................................................................. 5 4.5.Immunoglobulin for RSV – post BMT patients only ................................................................... 5 4.6.Ribavirin (unlicensed) ............................................................................................................... 6 4.7.Influenza A & B ...................................................................................................................... 7 4.8.Investigations ............................................................................................................................ 7 4.9.Treatment ................................................................................................................................. 7 4.10.Parainfluenza (HPIV) ............................................................................................................. 7 4.11.Parainfluenza的免疫球蛋白 - 仅BMT后患者................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 7 4.12。Adenovirus ............................................................................................................................. 8 4.13.Cidofovir (micro approval required) ....................................................................................... 8 4.14.SARS-CoV-2 ........................................................................................................................... 9 References ............................................................................................................................................ 9 Original authors .................................................................................................................................. 10 Audit .................................................................................................................................................... 10 Circulation ........................................................................................................................................... 10 Review ................................................................................................................................................. 11
为灰狗接种疫苗 - 行业实践指南
犬腺病毒 副流感病毒 (PI) 支气管败血性博德氏杆菌 (BB) 支气管败血性博德氏杆菌（或“BB”）是犬舍咳嗽的另一个关键成分。疫苗的犬舍咳嗽成分（PI 和 BB）可以注射、鼻内溶液或口服溶液（仅限 BB）的形式给药。
Robert Koch Institute（2025）
国家参考中心和顾问实验室在RKI芽孢杆菌•产生神经毒素的梭菌·封闭梭菌·隐球病和罕见的全身性真菌性·电子显微镜诊断感染性疾病中的电子显微镜诊断。 ·脊髓灰质炎和肺炎病毒·呼吸促性促性病毒，parainfluenza，metapneumoviruses·rotaviruess·沙门氏菌病和其他肠道病原体·葡萄球菌和肠球菌·肠球菌
何者正确？ A.可快速获得营养，但持续时间
A. 抗原转变 B. 抗原漂移 C. 气候变化 D. 金刚烷胺耐药性 79. 下列何者不属于副粘液病毒科（副粘液病毒科）？ A. 腮腺炎病毒（ 流行性腮腺炎病毒） B. 副流感病毒（ 副流感病毒） C. 麻疹病毒（ 麻疹病毒） D. 艾可病毒（ 艾可病毒）
狗疫苗协议
注意：第二个L2应为第一个L2后2-4周。第二次DHP疫苗不应在10周之前进行。在高风险的情况下，建议在16-20周内建议额外的犬parvo-C。如果小狗在其他地方接受了第一次疫苗，那不是犬种品牌，请在第二次小狗疫苗接种后2-4周提供canigen lepto2疫苗。这确保了同一品牌的两种钩端螺旋体病疫苗。成人重新启动：DHP + L2，然后2-4周后给出第二个L2。Canigen KC-任何有呼吸道感染风险的狗的鼻内疫苗（例如狗窝），包括parainfluenza病毒和Bordetella tronchiseptica。其他可用的疫苗：Canileish - 欧洲第一种针对犬利什曼病的疫苗。初级课程在6个月以上的免疫能力犬中相距3剂3周。免疫持续时间为1年，每年需要一剂量的助推器。在Canileish和任何其他疫苗接种之间留出2周。canigen狂犬病 - 非常适合旅行宠物。可以从12周龄开始，每3年助推器。
修订日期：2024 年 12 月 AN：01537/2024 第 1 页，共 10 页
疫苗接种计划：初级疫苗接种课程：单次注射应能对 10 周龄或以上的狗建立对犬瘟热、犬传染性肝炎和犬细小病毒感染引起的疾病的主动免疫力。如果需要早期保护，可对 6 周龄的幼犬进行第一剂接种，但由于母源性被动抗体可能会干扰对疫苗接种的反应，因此通常建议在 10 周龄或以上时进行最后一次接种。为了对副流感病毒成分产生最佳反应，动物应接种两次疫苗，间隔 2 - 4 周，最后一次接种应在 10 周龄或以上。如果 Nobivac DHPPi 的初始初级课程剂量延迟到 10 周龄或以上，则在 12 周龄或以上时接种一剂 Nobivac Pi 就足以建立对该成分的免疫力。